Hamid Shaaban, MD
Infectious Disease · Newark, NJNPI 1578854618
Payments from drug & device makers
Across 179 payments — averaging $26.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1K
- Incyte Corporation$492
- AstraZeneca$482
- Daiichi Sankyo Inc.$288
- Johnson & Johnson$179
- GSK$168
- plus $2K from 30 others
What the payments were for
- Food & beverage$3,05666%
- Education$3237%
- Other$1,28027%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 28 | $1,491 |
| Incyte Corporation | 22 | $492 |
| AstraZeneca(2 entities) | 17 | $482 |
| Daiichi Sankyo Inc. | 12 | $288 |
| Johnson & Johnson | 10 | $179 |
| GSK | 9 | $168 |
| Bayer | 7 | $154 |
| Pfizer | 9 | $145 |
| Merck | 7 | $121 |
| Seagen Inc. | 1 | $100 |
| Bristol Myers Squibb | 6 | $82 |
| Taiho Oncology, Inc. | 4 | $80 |
| Siemens Medical Solutions USA, Inc. | 1 | $80 |
| Amgen | 4 | $79 |
| E.r. Squibb & Sons, L.L.C. | 5 | $74 |
| Sanofi | 2 | $65 |
| Genentech USA, Inc. | 4 | $63 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $58 |
| Eisai Inc. | 3 | $56 |
| Mirati Therapeutics, Inc. | 3 | $50 |
| Rigel Pharmaceuticals, Inc. | 2 | $38 |
| Apellis Pharmaceuticals, Inc. | 2 | $36 |
| Astellas Pharma US Inc | 2 | $34 |
| Array Biopharma Inc | 2 | $33 |
| Sumitomo Pharma America, Inc. | 2 | $30 |
| Global Blood Therapeutics, Inc. | 2 | $29 |
| Beone Medicines USA, Inc. | 1 | $22 |
| Pharmaessentia USA Corporation | 1 | $18 |
| Boehringer Ingelheim | 1 | $16 |
| Octapharma USA, Inc. | 1 | $15 |
| Stemline Therapeutics Inc. | 1 | $15 |
| Tesaro, Inc. | 1 | $15 |
| Theratechnologies Inc. | 1 | $14 |
| Bio Products Laboratory USA, Inc. | 1 | $13 |
| Sanofi-aventis U.S. LLC | 1 | $11 |
| Tetraphase Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,659 in reported general payments places this provider in the 75th percentile of 334 infectious disease providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 16 | $296,548 |
| CalquenceAcalabrutinib Maleate | 19 | $289,355 |
| BrukinsaZanubrutinib | 17 | $252,681 |
| OpdivoNivolumab | 13 | $228,964 |
| Darzalex FasproDaratumumab-Hyaluronidase-Fihj | 14 | $197,491 |
| NubeqaDarolutamide | 12 | $154,297 |
| EliquisApixaban | 56 | $34,452 |
| XareltoRivaroxaban | 16 | $11,111 |
| Megestrol Acetate | 19 | $1,501 |
| Hydroxyurea | 20 | $819 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 22 | $608 |
| Prochlorperazine Maleate | 18 | $462 |
| Letrozole | 21 | $322 |
| Anastrozole | 17 | $316 |
| Zolpidem Tartrate | 22 | $213 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTagrisso, Calquence | $482 | $585,90335 claims |
| E.r. Squibb & Sons, L.L.C.Opdivo | $74 | $228,96413 claims |
| BayerNubeqa | $154 | $154,29712 claims |
| PfizerEliquis | $145 | $34,45256 claims |
| Johnson & JohnsonXarelto | $179 | $11,11116 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 334 infectious disease providers in New Jersey.
Other infectious disease in Newark
- Jihad SlimNewark$6.7M
- Shobha SwaminathanNewark$1.4M
- David AllandNewark$485K
- Maria SzabelaNewark$474K
- Sally HodderNewark$168K
- Debra ChewNewark$105K
- Tilly VarugheseNewark$98K
- Madhu SuryadevaraNewark$24K
- Lisa DeverNewark$18K
- Wanda FigueroaNewark$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.